fr en

Reagents and instruments for immunology, cell biology and molecular biology.

Quinacrine [83-89-6]

Print

Cat# HY-13735-10mg

Size : 10mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Description

Quinacrine (Acriquine) is an antimalarial and anti-cancer agent. Quinacrine also inhibits human aldehyde oxidase (IC₅₀: 3.3 μM). Quinacrine has affinity for nucleic acids, and stains DNA and RNA in fixed cells (Ex/Em: 436/525 nm)^[1]^[2]^[3]^[4]^[7].

Cellular Effect

Cell Line	Type	Value	Description	References
184B5	IC₅₀	4.96 μM Compound: QC	Cytotoxicity against human 184B5 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human 184B5 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
184B5	IC₅₀	4.96 μM Compound: Quinacrine	Antiproliferative activity against human 184B5 cells after 48 hrs by SRB assay Antiproliferative activity against human 184B5 cells after 48 hrs by SRB assay	[PMID: 29232580]
BHK-21	CC₅₀	18.59 μM Compound: 40	Cytotoxicity against BHK21 cells after 24 to 48 hrs by CCK8 assay Cytotoxicity against BHK21 cells after 24 to 48 hrs by CCK8 assay	[PMID: 31549836]
BHK-21	CC₅₀	19.8 μM Compound: 18	Cytotoxicity against hamster BHK-21 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against hamster BHK-21 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36940609]
CHO-AA8	IC₅₀	1.7 μM Compound: 4 (quinacrine mustard)	In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8 In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8	[PMID: 2319563]
HeLa	IC₅₀	1.05 μM Compound: Quinacrine	Antiviral activity against Ebolavirus infected in human HeLa cells assessed as reduction in viral replication incubated for 48 hrs by luminescence based assay Antiviral activity against Ebolavirus infected in human HeLa cells assessed as reduction in viral replication incubated for 48 hrs by luminescence based assay	[PMID: 32832035]
Hepatocyte	IC₅₀	3 × 10⁴nM Compound: Quinacrine	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
Hepatocyte	IC₅₀	3 x 10⁴nM Compound: Quinacrine	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
Hepatocyte	IC₅₀	73 μM Compound: 9 Quinacrine	Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes	[PMID: 15225721]
HepG2	CC₅₀	7.6 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay	[PMID: 33479683]
HepG2	CC₅₀	9.78 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue assay	[PMID: 24354316]
HepG2	EC₅₀	10.44 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by Alamar blue assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by Alamar blue assay	[PMID: 27992217]
HepG2	EC₅₀	10.44 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue-based assay Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue-based assay	[PMID: 28740614]
HepG2	EC₅₀	11.9 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 27788467]
HepG2	EC₅₀	7653.7 μM Compound: Quinacrine	Cytotoxicity against human HepG2 cells after 48 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 48 hrs by alamar blue assay	[PMID: 30655955]
HT-1080	IC₅₀	29 μM Compound: Quinacrine	Anticancer activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
HT-22	EC₅₀	9.09 μM Compound: Quinacrine	Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay	[PMID: 24602904]
HT-29	IC₅₀	55 μM Compound: Quinacrine	Concentration required to inhibit colony formation by 50% in human colon carcinoma HT-29 cells Concentration required to inhibit colony formation by 50% in human colon carcinoma HT-29 cells	[PMID: 8289202]
Huh-7	CC₅₀	19.61 μM Compound: GNF-Pf-5448	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Mast cell	IC₅₀	13.7 μM Compound: Mepacrine	Inhibition of compound 48/80-stimulated beta-glucuronidase release in rat peritoneal mast cell Inhibition of compound 48/80-stimulated beta-glucuronidase release in rat peritoneal mast cell	[PMID: 15568764]
Mast cell	IC₅₀	23.3 μM Compound: Mepacrine	Inhibition of compound 48/80-stimulated histamine release in rat mast cell Inhibition of compound 48/80-stimulated histamine release in rat mast cell	[PMID: 15568764]
MCF7	IC₅₀	4.19 μM Compound: QC	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
MCF7	IC₅₀	4.19 μM Compound: Quinacrine	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 29232580]
MCF7	IC₅₀	7.5 μM Compound: Quinacrine	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30684866]
MDA-MB-231	IC₅₀	3.25 μM Compound: QC	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
MDA-MB-231	IC₅₀	3.25 μM Compound: Quinacrine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 29232580]
MDA-MB-468	IC₅₀	3.96 μM Compound: QC	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 28586716]
MDA-MB-468	IC₅₀	3.96 μM Compound: Quinacrine	Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by SRB assay	[PMID: 29232580]
N2a #58 F3	EC₅₀	1.88 μM Compound: Quinacrine	Antiprion activity against human prion protein Fukuoka-1 infected mouse F3 cells assessed as reduction of PrPSc level by Western blot method Antiprion activity against human prion protein Fukuoka-1 infected mouse F3 cells assessed as reduction of PrPSc level by Western blot method	[PMID: 21531054]
N2a #58 F3	EC₅₀	1.88 μM Compound: quinacrine	Antiprion activity against human prion Fukuoka-1 infected mouse F3 cells assessed as reduction of scrapie prion protein accumulation Antiprion activity against human prion Fukuoka-1 infected mouse F3 cells assessed as reduction of scrapie prion protein accumulation	[PMID: 18556207]
ScN2a	EC₅₀	0.23 μM Compound: quinacrine	Antiprion activity against scrapie prion protein RML infected mouse ScN2a cells assessed as reduction of scrapie prion protein accumulation by immunoblot analysis Antiprion activity against scrapie prion protein RML infected mouse ScN2a cells assessed as reduction of scrapie prion protein accumulation by immunoblot analysis	[PMID: 18556207]
ScN2a	EC₅₀	0.23 μM Compound: Quinacrine	Antiprion activity against mouse prion protein RML infected mouse ScN2a cells assessed as reduction of PrPSc level by Western blot method Antiprion activity against mouse prion protein RML infected mouse ScN2a cells assessed as reduction of PrPSc level by Western blot method	[PMID: 21531054]
ScN2a	EC₅₀	0.3 μM Compound: Quinacrine	Antiprion activity against Scrapie prion protein-mediated scrapie in RML mouse ScN2a cells assessed as reduction of PrP-Sc level after 6 days by immunoblotting Antiprion activity against Scrapie prion protein-mediated scrapie in RML mouse ScN2a cells assessed as reduction of PrP-Sc level after 6 days by immunoblotting	[PMID: 19842664]
ScN2a	EC₅₀	0.3 μM Compound: Quinacrine	Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells	[PMID: 12904059]
ScN2a	EC₅₀	0.5 μM Compound: 1	Inhibition of PrPSc accumulation in mouse ScN2a cell line relative to control Inhibition of PrPSc accumulation in mouse ScN2a cell line relative to control	[PMID: 16860557]
ScN2a	EC₅₀	0.8 μM Compound: quinacrine	Reduction of PrPSC accumulation in ScN2a cells Reduction of PrPSC accumulation in ScN2a cells	[PMID: 17201410]
ScN2a	EC₅₀	300 nM Compound: quinacrine	Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells	[PMID: 17064077]
SH-SY5Y	IC₅₀	8.57 μM Compound: Quinacrine	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
U-251	IC₅₀	5 μM Compound: 81	Antiproliferative activity against human U251 cells by MTT assay Antiproliferative activity against human U251 cells by MTT assay	[PMID: 30583248]
U2OS	EC₅₀	0.25 μM Compound: 157	Inhibition of autophagy in human U2OS cells expressing tfLC3 incubated for 3 hrs by fluorescent microscopy Inhibition of autophagy in human U2OS cells expressing tfLC3 incubated for 3 hrs by fluorescent microscopy	[PMID: 36283182]
U2OS	IC₅₀	2.5 μM Compound: 157	Cytotoxicity against human U2OS cells Cytotoxicity against human U2OS cells	[PMID: 36283182]
UV4	IC₅₀	0.14 μM Compound: 4 (quinacrine mustard)	In vitro cytotoxicity against transformed chinese hamster fibroblast line UV4. In vitro cytotoxicity against transformed chinese hamster fibroblast line UV4.	[PMID: 2319563]
Ventricular myocyte	IC₅₀	5.2 μM Compound: Mepacrine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]
Vero	CC₅₀	14.71 μM Compound: Quinacrine	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	EC₅₀	2.27 μM Compound: 40	Antiviral activity against Zika virus MR766 infected in African green monkey Vero cells by plaque assay Antiviral activity against Zika virus MR766 infected in African green monkey Vero cells by plaque assay	[PMID: 31549836]
Vero	IC₅₀	>50 μM Compound: Quinacrine	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
WIL2-NS	CC₅₀	4.8 μM Compound: Quinacrine	Cytotoxicity against human WIL2-NS cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay Cytotoxicity against human WIL2-NS cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay	[PMID: 33479683]

In Vitro

Quinacrine inhibits human and rabbit aldehyde oxidase, with IC₅₀s of 3.3 μM and 10 μM respectively^[2].
Quinacrine blocks voltage-dependent sodium channels (IC₅₀: 3.3 μM)^[3].
Quinacrine (100 μM) is also a PLA2 inhibitor^[4].
Quinacrine (0-20 μM, 24 h) inhibits the growth of SGC-7901 cells, and induces cell apoptosis^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[7]

Cell Line:	SGC-7901 cell
Concentration:	0, 5, 10, 15, 20 μM
Incubation Time:	24 h
Result:	Inhibited cell growth with an IC₅₀ value of 16.18 μM.

In Vivo

Quinacrine (3-30 mg/kg, i.p., once daily for three days) has protective effect against glycerol-induced acute kidney injury in rats^[5].
Quinacrine (2.5-10 mg/kg, i.p., once daily for eight weeks) has protective effect against Cyclosporine-induced nephrotoxicity in rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Acute kidney injury rat model^[5]
Dosage:	3-30 mg/kg
Administration:	i.p.
Result:	Attenuated glycerol induced structural and functional changes in kidney.

Molecular Weight

399.96

Formula

C₂₃H₃₀ClN₃O

CAS No.

83-89-6

Appearance

Oil

Color

Light yellow to yellow

SMILES

CC(CCCN(CC)CC)NC1=C2C=C(C=CC2=NC3=CC(Cl)=CC=C31)OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (125.01 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5003 mL	12.5013 mL	25.0025 mL
5 mM	0.5001 mL	2.5003 mL	5.0005 mL
10 mM	0.2500 mL	1.2501 mL	2.5003 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (12.50 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

Purity & Documentation

Purity: 98.20%

Data Sheet (281 KB) SDS (558 KB)

COA (252 KB) HNMR (136 KB) RP-HPLC (168 KB) LCMS (105 KB)

Handling Instructions (2659 KB)

References

[1]. Vogtherr M, et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem. 2003 Aug 14;46(17):3563-4. [Content Brief]

[2]. Pryde DC, et al. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem. 2010 Dec 23;53(24):8441-60. [Content Brief]

[3]. McNeal ET, et al. [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs. J Med Chem. 1985 Mar;28(3):381-8. [Content Brief]

[4]. Caro AA,et al. Role of phospholipase A2 activation and calcium in CYP2E1-dependent toxicity in HepG2 cells. J Biol Chem. 2003 Sep 5;278(36):33866-77. [Content Brief]

[5]. Al Asmari AK, et al. Protective effect of quinacrine against glycerol-induced acute kidney injury in rats. BMC Nephrol. 2017 Jan 28;18(1):41. [Content Brief]

[6]. al Khader A, et al. Quinacrine attenuates cyclosporine-induced nephrotoxicity in rats. Transplantation. 1996 Aug 27;62(4):427-35. [Content Brief]

[7]. Wu X, et al. Quinacrine Inhibits Cell Growth and Induces Apoptosis in Human Gastric Cancer Cell Line SGC-7901. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):52-64. [Content Brief]

Quinacrine [83-89-6]

Cat# HY-13735-10mg

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

Quinacrine Related Antibodies